Update of systemic immunotherapy for advanced urothelial carcinoma

Benjamin A. Gartrell, Tianfang He, Janaki N. Sharma, Guru Sonpavde

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose Until recently, therapeutic options for metastatic urothelial carcinoma (UC) were limited to cytotoxic chemotherapy. Cisplatin-based combination chemotherapy has proven benefit in the perioperative settings for muscle-invasive disease and for metastatic disease. A large proportion of patients is cisplatin-ineligible and limited to less effective chemotherapeutic options. However, treatment options have recently expanded with the development of systemic immunotherapy with checkpoint inhibitors (CPIs).Herein we review the clinical trial data supporting the use of CPIs in UC. We also describe ongoing clinical trials that are exploring CPIs in novel combinations and in a variety of disease settings. Methods A comprehensive literature review was performed using Medline/Pubmed and clinical trials. Results/Conclusions Based on results of the IMvigor 210 clinical trial, the anti-programmed death-ligand1 antibody atezolizumab gained regulatory approval in May 2016 for use in locally advanced and metastatic UC in patients with progression of disease despite prior platinum-based chemotherapy. Since that time, additional CPIs (avelumab, durvalumab, nivolumab, and pembrolizumab) have gained regulatory approval in the postplatinum setting. The approval of pembrolizumab was supported by KEYNOTE-045, the first reported randomized, phase III trial of a CPI in UC. Atezolizumab and pembrolizumab are also approved for first-line therapy for cisplatin-ineligible patients with locally advanced or metastatic disease. The rapid expansion of therapeutic options in UC has shifted the treatment paradigm.

Original languageEnglish (US)
Pages (from-to)678-686
Number of pages9
JournalUrologic Oncology: Seminars and Original Investigations
Volume35
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Immunotherapy
Carcinoma
Clinical Trials
Cisplatin
Therapeutics
Drug Therapy
Combination Drug Therapy
Platinum
PubMed
Disease Progression
Muscles
Antibodies
pembrolizumab
MPDL3280A

Keywords

  • Checkpoint inhibitors
  • Immunotherapy
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Update of systemic immunotherapy for advanced urothelial carcinoma. / Gartrell, Benjamin A.; He, Tianfang; Sharma, Janaki N.; Sonpavde, Guru.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 35, No. 12, 01.12.2017, p. 678-686.

Research output: Contribution to journalReview article

Gartrell, Benjamin A. ; He, Tianfang ; Sharma, Janaki N. ; Sonpavde, Guru. / Update of systemic immunotherapy for advanced urothelial carcinoma. In: Urologic Oncology: Seminars and Original Investigations. 2017 ; Vol. 35, No. 12. pp. 678-686.
@article{9b7ccb47f6684aa6914e4e741b8f8ece,
title = "Update of systemic immunotherapy for advanced urothelial carcinoma",
abstract = "Purpose Until recently, therapeutic options for metastatic urothelial carcinoma (UC) were limited to cytotoxic chemotherapy. Cisplatin-based combination chemotherapy has proven benefit in the perioperative settings for muscle-invasive disease and for metastatic disease. A large proportion of patients is cisplatin-ineligible and limited to less effective chemotherapeutic options. However, treatment options have recently expanded with the development of systemic immunotherapy with checkpoint inhibitors (CPIs).Herein we review the clinical trial data supporting the use of CPIs in UC. We also describe ongoing clinical trials that are exploring CPIs in novel combinations and in a variety of disease settings. Methods A comprehensive literature review was performed using Medline/Pubmed and clinical trials. Results/Conclusions Based on results of the IMvigor 210 clinical trial, the anti-programmed death-ligand1 antibody atezolizumab gained regulatory approval in May 2016 for use in locally advanced and metastatic UC in patients with progression of disease despite prior platinum-based chemotherapy. Since that time, additional CPIs (avelumab, durvalumab, nivolumab, and pembrolizumab) have gained regulatory approval in the postplatinum setting. The approval of pembrolizumab was supported by KEYNOTE-045, the first reported randomized, phase III trial of a CPI in UC. Atezolizumab and pembrolizumab are also approved for first-line therapy for cisplatin-ineligible patients with locally advanced or metastatic disease. The rapid expansion of therapeutic options in UC has shifted the treatment paradigm.",
keywords = "Checkpoint inhibitors, Immunotherapy, Urothelial carcinoma",
author = "Gartrell, {Benjamin A.} and Tianfang He and Sharma, {Janaki N.} and Guru Sonpavde",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.urolonc.2017.09.021",
language = "English (US)",
volume = "35",
pages = "678--686",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Update of systemic immunotherapy for advanced urothelial carcinoma

AU - Gartrell, Benjamin A.

AU - He, Tianfang

AU - Sharma, Janaki N.

AU - Sonpavde, Guru

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose Until recently, therapeutic options for metastatic urothelial carcinoma (UC) were limited to cytotoxic chemotherapy. Cisplatin-based combination chemotherapy has proven benefit in the perioperative settings for muscle-invasive disease and for metastatic disease. A large proportion of patients is cisplatin-ineligible and limited to less effective chemotherapeutic options. However, treatment options have recently expanded with the development of systemic immunotherapy with checkpoint inhibitors (CPIs).Herein we review the clinical trial data supporting the use of CPIs in UC. We also describe ongoing clinical trials that are exploring CPIs in novel combinations and in a variety of disease settings. Methods A comprehensive literature review was performed using Medline/Pubmed and clinical trials. Results/Conclusions Based on results of the IMvigor 210 clinical trial, the anti-programmed death-ligand1 antibody atezolizumab gained regulatory approval in May 2016 for use in locally advanced and metastatic UC in patients with progression of disease despite prior platinum-based chemotherapy. Since that time, additional CPIs (avelumab, durvalumab, nivolumab, and pembrolizumab) have gained regulatory approval in the postplatinum setting. The approval of pembrolizumab was supported by KEYNOTE-045, the first reported randomized, phase III trial of a CPI in UC. Atezolizumab and pembrolizumab are also approved for first-line therapy for cisplatin-ineligible patients with locally advanced or metastatic disease. The rapid expansion of therapeutic options in UC has shifted the treatment paradigm.

AB - Purpose Until recently, therapeutic options for metastatic urothelial carcinoma (UC) were limited to cytotoxic chemotherapy. Cisplatin-based combination chemotherapy has proven benefit in the perioperative settings for muscle-invasive disease and for metastatic disease. A large proportion of patients is cisplatin-ineligible and limited to less effective chemotherapeutic options. However, treatment options have recently expanded with the development of systemic immunotherapy with checkpoint inhibitors (CPIs).Herein we review the clinical trial data supporting the use of CPIs in UC. We also describe ongoing clinical trials that are exploring CPIs in novel combinations and in a variety of disease settings. Methods A comprehensive literature review was performed using Medline/Pubmed and clinical trials. Results/Conclusions Based on results of the IMvigor 210 clinical trial, the anti-programmed death-ligand1 antibody atezolizumab gained regulatory approval in May 2016 for use in locally advanced and metastatic UC in patients with progression of disease despite prior platinum-based chemotherapy. Since that time, additional CPIs (avelumab, durvalumab, nivolumab, and pembrolizumab) have gained regulatory approval in the postplatinum setting. The approval of pembrolizumab was supported by KEYNOTE-045, the first reported randomized, phase III trial of a CPI in UC. Atezolizumab and pembrolizumab are also approved for first-line therapy for cisplatin-ineligible patients with locally advanced or metastatic disease. The rapid expansion of therapeutic options in UC has shifted the treatment paradigm.

KW - Checkpoint inhibitors

KW - Immunotherapy

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85033481721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033481721&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2017.09.021

DO - 10.1016/j.urolonc.2017.09.021

M3 - Review article

C2 - 29079131

AN - SCOPUS:85033481721

VL - 35

SP - 678

EP - 686

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 12

ER -